Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16785530 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Ohmura-Hoshino M, et al. (2006) Inhibition of MHC class II expression and immune responses by c-MIR. J Immunol 177, 341-54 16785530
Download Sites

K225-ub - HLA-DRB1 (mouse)
Orthologous residues
HLA‑DRB1 (human): K227‑ub, HLA‑DRB1 iso2 (human): K227‑ub, HLA‑DRB1 iso3 (human): K227‑ub, HLA‑DRB1 (mouse): K225‑ub
Characterization
 Methods used to characterize site in vivo immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting
 Disease tissue studied:  lymphoma, B cell lymphoma
 Relevant cell lines - cell types - tissues:  293T (epithelial), A20.2J (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
UBIQUITIN LIGASE MARCH8 (human) transfection of inactive enzyme, transfection of wild-type enzyme
Downstream Regulation
 Effect of modification (function):  protein degradation
 Effect of modification (process):  endocytosis, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.